Life Sciences & Med Device Companies Considerations Amid COVID - McDermott

Critical Business Considerations for Life Sciences and Medical Device Companies Amid the COVID-19 Pandemic


Life sciences and medical device companies are dealing with an unprecedented crisis. The industry is not only managing the impact of Coronavirus (COVID-19), they are also a solution provider. Companies are rapidly adapting products, services, facilities and distribution channels to aid in the pandemic response. Simultaneously, they must maintain shareholder value, navigate highly complex regulatory hurdles and compliance obligations while rethinking strategies for growth in a post-COVID-19 world.

Join a team of seasoned professionals from McDermott Will & Emery and Ernst & Young, LLP for insights and guidance on critical COVID-19-related operational, regulatory and legal developments, including:

  • Supply chain adaption and compliance
  • R&D, clinical trials and the FDA
  • The CARES act and accessing government funds
  • Restructuring and solvency strategies

See full agenda and speaker information below.

With the flood of information available to you, we want to ensure you have the opportunity to get answers to any questions that will help you assess your particular business needs.

Please note areas where you could use additional guidance in the “Questions & Comments” box so we can address the issues that are most important to you.

Registration Information

12:00 – 2:00 PM (EDT)



12:00 – 12:05pm

Opening Remarks
Kristian Werling & Stephen Bernstein, Co-Chairs, Life Sciences Industry Practice, McDermott Will & Emery

12:05 – 12:15pm

Faring through Recessions: A History of Resiliency and Lessons Learned in the Life Sciences Industry
Arda Ural, Principal & Life Sciences Strategy & Operations Practice Lead

12:15 – 12:40 pm

Reconfiguring R&D and Clinical Trials: FDA Interactions and Approvals
Moderator: Stephen Bernstein, Co-Chair Life Sciences Industry Practice, McDermott Will & Emery
Nick Davies, Partner, EY Parthenon
Vernessa Pollard, Chair, FDA Practice, McDermott Will & Emery

12:40 – 1:05 pm

Focusing on the Supply Chain: Manufacturing Inputs, Import/Export, Logistics and Compliance
Moderator: Alex Jung, Managing Director, EY-Parthenon
Katharine O’Connor, Partner, McDermott Will & Emery
Derron Stark, Strategy & Operations – Executive Director, Ernst & Young

1:05 – 1:30 pm

Government Assistance Programs, CARES Act: Accessing Funding Supports
Moderator: Kristian Werling, Co-Chair, Life Sciences Industry Practice, McDermott Will & Emery
Ray Beeman, Principal and Co-leader, Washington Council Ernst & Young
James Kim, Partner, McDermott Will & Emery

1:30 – 1:55 pm

Restructuring & Solvency: Creditors, Distressed Vendors & Operating through the Thicket
Moderator: Felicia Perlman, Partner, McDermott Will & Emery
Maris Kandestin, Partner, McDermott Will & Emery
Guarav Malhotra, Principal, Ernst & Young

1:55 – 2:00 pm

Closing Remarks